Pamela F. Weiss

Dec 10, 2024 | acrjournals.onlinelibrary.wiley.com | Michael Shishov |Pamela F. Weiss |Deborah Levy |Déborah Levy |Joyce Chang

Supporting Information Filename Description acr25482-sup-0001-Disclosureform.pdfPDF document, 1.9 MB Disclosure Form

Dec 1, 2024 | jrheum.org | Laura Coates |Georg Schett |Chenchen Wang |Pamela F. Weiss

Key Indexing Terms:ankylosing spondylitisoutcomesspondyloarthropathyIntroductionThe advances in our understanding of pathogenesis, novel therapeutics, and nonpharmacologic interventions have revolutionized the management of axial spondyloarthritis (axSpA).

Oct 16, 2024 | jrheum.org | Laura Coates |Georg Schett |Chenchen Wang |Pamela F. Weiss

AbstractA program focused on pathogenesis, clinical trial design, and nonpharmacologic mind-body therapy for of spondyloarthritis (SpA) was presented at the Spondylitis Association of America Unmet Needs Conference IV. SpA pathogenesis is incompletely understood but involves a complex set of drivers, including genetics, biomechanical stress, and microbial factors. Affected tissues may include axial and peripheral joints, entheses, skin, uvea, and intestines.